Tubular nephrotoxicity induced by docetaxel in non-small-cell lung cancer patients

被引：20

作者：

Takimoto, Takayuki ^{[1
]}

Nakabori, Tasuku ^{[1
]}

Osa, Akio ^{[1
]}

Morita, Satomu ^{[1
]}

Terada, Haruko ^{[1
]}

Oseto, Susumu ^{[1
]}

Iwazawa, Takashi ^{[2
]}

Abe, Kinya ^{[1
]}

机构：

[1] Toyonaka City Hosp, Dept Internal Med, Toyonaka, Osaka 5608565, Japan

[2] Toyonaka City Hosp, Dept Surg, Toyonaka, Osaka 5608565, Japan

来源：

INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 17卷 / 04期

关键词：

Non-small-cell lung cancer (NSCLC); Chronic renal failure; Docetaxel; Tubular nephrotoxicity; beta(2)-Microglobulin; RENAL-FUNCTION; CISPLATIN; CHEMOTHERAPY; PLATINUM; TAXOTERE;

D O I：

10.1007/s10147-011-0304-5

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Renal dysfunction is a characteristic of many patients with cancer; however, a standard therapy has not been established for stage III or IV non-small-cell lung cancer (NSCLC) complicated with chronic renal failure. Docetaxel has a proven significant activity against NSCLC. This agent is predominantly eliminated by hepatobiliary extraction and is safe in patients with renal failure, including dialysis patients. Docetaxel is, thus, a therapeutic option in that patient population. Here, we report acute tubular nephrotoxicity secondary to docetaxel in NSCLC patients, even in patients with normal renal function. Little is known about tubular nephrotoxicity induced by docetaxel; however, oncologists should be aware of its possibility.

引用

页码：395 / 398

页数：4

共 50 条

[21] Docetaxel-based induction therapy prior to radiotherapy with or without docetaxel for non-small-cell lung cancer
G V Scagliotti
A Szczesna
R Ramlau
F Cardenal
K Mattson
N Van Zandwijk
A Price
B Lebeau
J Debus
C Manegold
British Journal of Cancer, 2006, 94 : 1375 - 1382
[22] Phase I study of docetaxel and irinotecan in patients with advanced non-small-cell lung cancer
Nogami, N
Harita, S
Ueoka, H
Yonei, T
Kiura, K
Kamei, H
Tabata, M
Segawa, Y
Gemba, K
Tanimoto, M
LUNG CANCER, 2004, 45 (01) : 85 - 91
[23] Docetaxel and non-small cell lung cancer
Le Guen, Y
Le Cesne, A
BULLETIN DU CANCER, 2004, 91 (03) : 263 - 270
[24] Prospective Observational Study of Ramucirumab Plus Docetaxel After Combined Chemoimmunotherapy in Patients With Non-Small-Cell Lung Cancer
Katayama, Yuki
Yamada, Tadaaki
Sawada, Ryo
Kawachi, Hayato
Morimoto, Kenji
Watanabe, Satoshi
Watanabe, Kageaki
Takeda, Takayuki
Chihara, Yusuke
Shiotsu, Shinsuke
Hibino, Makoto
Harada, Taishi
Nishioka, Naoya
Iwasaku, Masahiro
Tokuda, Shinsaku
Takayama, Koichi
ONCOLOGIST, 2024, : e681 - e689
[25] Defining the issues in the treatment of elderly patients with advanced non-small-cell lung cancer
Gajra, Ajeet
LUNG CANCER MANAGEMENT, 2015, 4 (01) : 17 - 30
[26] The SATURN trial: the value of maintenance erlotinib in patients with non-small-cell lung cancer
Neal, Joel W.
FUTURE ONCOLOGY, 2010, 6 (12) : 1827 - 1832
[27] Durvalumab in non-small-cell lung cancer patients: current developments
Mezquita, Laura
Planchard, David
FUTURE ONCOLOGY, 2018, 14 (03) : 205 - 222
[28] Induction combination chemotherapy with docetaxel and carboplatin in advanced non-small-cell lung cancer
Herse, B
Dalichau, H
Wörmann, B
Hemmerlein, B
Schmidberger, H
Hess, CF
Hannemann, P
Criée, CP
Hiddemann, W
Griesinger, F
THORACIC AND CARDIOVASCULAR SURGEON, 1998, 46 (05) : 298 - 302
[29] Effect of rapamycin-induced tumor vessel thrombosis combined with docetaxel in non-small-cell lung cancer
Xu, Liqin
Qin, Yan
Huang, Jianfei
Qin, Jing
Gu, Jun
Zhu, Huijun
Liu, Hong
Cai, Yifeng
Wu, Xinhua
Feng, Jian
ANTI-CANCER DRUGS, 2013, 24 (04) : 406 - 414
[30] A dose-escalation study of pemetrexed and docetaxel in non-small-cell lung cancer
Kotsakis, Athanasios
Agelaki, Sophia
Vardakis, Nikolaos
Stathopoulos, George
Vamvakas, Lambros
Kalykaki, Antonia
Kentepozidis, Nikolaos
Kontopodis, Emmanouel
Sfakiotaki, Georgia
Mavroudis, Dimitris
Georgoulias, Vassilis
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2011, 68 (02) : 415 - 422

← 1 2 3 4 5 →